Back to NVSEFView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
View Full LandscapeDrug Information
Target Indication
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Clinical Trial
NCT05445843Last updated: 2/14/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
FingolimodPhase 3
Multiple Sclerosis
dovitinibPhase 3
Solid Tumors
MF59-eH1N1_fPhase 3
Influenza
Glycopyrronium bromidePhase 3
Chronic Obstructive Pulmonary Disease
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3
Swine-Origin Influenza A H1N1 Virus
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts